Evidence map›Paper›PMID 31453376›Full record

ArticleNPJ digital medicine2019

Translating clinical trial results into personalized recommendations by considering multiple outcomes and subjective views.

Noa Dagan, Chandra J Cohen-Stavi, Meytal Avgil Tsadok, Morton Leibowitz, Moshe Hoshen, Tomas Karpati, Amichay Akriv, Ilan Gofer, Harel Gilutz, Eduardo Podjarny and 2 more

Abstract read
In one paragraph

Article in NPJ digital medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Article
  6. Addressing bias in prediction models by improving subpopulation calibration.Journal of the American Medical Informatics Association : JAMIA · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Noa Dagan1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
Chandra J Cohen-Stavi1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
Meytal Avgil Tsadok1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
Morton Leibowitz1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
Moshe Hoshen1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
Tomas Karpati1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.ORCID 0000-0003-2650-6192
Amichay Akriv1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
Ilan Gofer1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
Harel Gilutz1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
Eduardo Podjarny4ADAM Institute of High Blood Pressure, Clalit Health Services, Hertzlia, Israel.
Eitan Bachmat1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.
Ran D Balicer1Clalit Research Institute, Clalit Health Services, Tel Aviv, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Currently, clinicians rely mostly on population-level treatment effects from RCTs, usually considering the treatment's benefits. This study proposes a process, focused on practical usability, for translating RCT data into personalized treatment recommendations that weighs benefits against harms and integrates subjective perceptions of relative severity. Intensive blood pressure treatment (IBPT) was selected as the test case to demonstrate the suggested process, which was divided into three phases: (1) Prediction models were developed using the Systolic Blood-Pressure Intervention Trial (SPRINT) data for benefits and adverse events of IBPT. The models were externally validated using retrospective Clalit Health Services (CHS) data; (2) Predicted risk reductions and increases from these models were used to create a yes/no IBPT recommendation by calculating a severity-weighted benefit-to-harm ratio; (3) Analysis outputs were summarized in a decision support tool. Based on the individual benefit-to-harm ratios, 62 and 84% of the SPRINT and CHS populations, respectively, would theoretically be recommended IBPT. The original SPRINT trial results of significant decrease in cardiovascular outcomes following IBPT persisted only in the group that received a "yes-treatment" recommendation by the suggested process, while the rate of serious adverse events was slightly higher in the "no-treatment" recommendation group. This process can be used to translate RCT data into individualized recommendations by identifying patients for whom the treatment's benefits outweigh the harms, while considering subjective views of perceived severity of the different outcomes. The proposed approach emphasizes clinical practicality by mimicking physicians' clinical decision-making process and integrating all recommendation outputs into a usable decision support tool.

Indexed as

DatabasesPreventive medicine

Identifiers

PMID31453376
PMCPMC6704144

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.